Rus­si­a's war in Ukraine is now de­lay­ing da­ta read­outs, as Tri­ci­da says its sec­ond-chance tri­al needs more time

A small cap biotech re­port­ed Wednes­day that the Russ­ian in­va­sion of Ukraine will de­lay the in­ter­im analy­sis for a large study, sug­gest­ing the war could bring new chal­lenges to the in­dus­try.

Tri­ci­da said Wednes­day af­ter­noon it will have to de­lay the da­ta read­out for its ex­per­i­men­tal CKD drug vev­er­imer by at least one quar­ter, from the third quar­ter of this year to the fourth quar­ter. About 15% of pa­tients en­rolled in the 1,600-per­son study are from Ukraine, the com­pa­ny said, lead­ing to what the biotech calls “an­tic­i­pat­ed dis­rup­tion and/or de­lays” in col­lect­ing the da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER